Influx Healthtech IPO GMP Price and More: Sees High Demand, Poised for NSE SME Listing
Mumbai, India – Influx Healthtech Limited, a healthcare-focused contract development and manufacturing organization (CDMO), has successfully concluded its Initial Public Offering (IPO) on the NSE SME platform, receiving an overwhelming response from investors. The ₹55.63 crore issue, which opened on June 18, 2025, and closed on June 20, 2025, saw significant oversubscription across all categories, indicating strong market confidence.
Company Profile: A Specialist in Healthcare Manufacturing
Incorporated in September 2020, Influx Healthtech Limited has quickly established itself as a prominent player in the healthcare manufacturing sector. The Mumbai-based company operates as a Contract Development and Manufacturing Organization (CDMO), providing end-to-end manufacturing services to Business-to-Business (B2B) clients. Its diverse product portfolio spans nutraceuticals, cosmetics, Ayurvedic/herbal products, veterinary feed supplements, and homecare solutions.
Influx Healthtech boasts three fully equipped and certified manufacturing facilities in Thane, Maharashtra, covering approximately 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft. These facilities adhere to stringent international standards, including GMP (Good Manufacturing Practice), HACCP, ISO 22000, and Halal accreditations, ensuring high-quality and scalable production.
Financially, the company has demonstrated consistent growth. For Fiscal Year 2025, Influx Healthtech reported a revenue from operations of ₹104.85 crore and a profit after tax (PAT) of ₹13.37 crore, up from ₹99.96 crore revenue and ₹11.13 crore PAT in FY24.
IPO Details: Price, Dates, and Issue Structure
The Influx Healthtech IPO is a book-building issue with a total size of ₹55.63 crore. It comprised a fresh issue of 46.94 lakh shares aggregating to ₹45.07 crore, and an Offer for Sale (OFS) of 11.00 lakh shares amounting to ₹10.56 crore.
- IPO Open Date: Wednesday, June 18, 2025
- IPO Close Date: Friday, June 20, 2025
- Price Band: ₹91 to ₹96 per equity share
- Face Value: ₹10 per share
- Lot Size: 1,200 shares (Minimum investment for retail investors: ₹1,15,200 at the upper price band)
- Listing At: NSE SME
The company also raised ₹16.67 crore from anchor investors on June 17, 2025, at the upper price band of ₹96 per share.
Subscription Status: Overwhelming Investor Response
The Influx Healthtech IPO received an enthusiastic response from all investor categories, with the issue being oversubscribed by 34.13 times by the close of bidding on June 20, 2025.
| Investor Category | Subscription (times) |
|---|---|
| Qualified Institutional Buyers (QIB) | 1.71 |
| Non-Institutional Investors (NII) | 48.18 |
| Retail Individual Investors (RII) | 46.63 |
| Total | 34.13 |
Retail investors showed particularly strong interest, subscribing over 46 times their allotted quota.
Grey Market Premium (GMP) Performance
The Grey Market Premium (GMP) for Influx Healthtech IPO has been closely watched, indicating robust investor sentiment.
| Date | GMP (per share) | Implied Listing Premium (over ₹96) |
|---|---|---|
| June 13, 2025 | ₹16 | 16.67% |
| June 14, 2025 | ₹24 | 25.00% |
| June 16, 2025 | ₹22 | 22.92% |
| June 17, 2025 | ₹35 | 36.46% |
| June 18, 2025 (Open) | ₹40-45 | 41.67%-46.88% |
| June 19, 2025 | ₹45 | 46.88% |
| June 20, 2025 (Close) | ₹38 | 39.58% |
(Note: GMP is an unofficial indicator based on market speculation and is not a guaranteed predictor of listing performance.)
Allotment and Listing Dates
- Tentative Allotment Date: Monday, June 23, 2025
- Initiation of Refunds: Tuesday, June 24, 2025
- Credit of Shares to Demat Account: Tuesday, June 24, 2025
- Tentative Listing Date (NSE SME): Wednesday, June 25, 2025
Influx Healthtech is now set to make its debut on the NSE SME, with market participants eagerly anticipating its listing performance following the strong subscription figures and healthy grey market premium. The company plans to utilize the IPO proceeds for funding capital expenditure for new manufacturing facilities in its Nutraceutical and Veterinary Food Divisions, purchasing machinery for its Homecare and Cosmetic Divisions, and for general corporate purposes.